Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
strategic options
Biotech
Prelude calls it curtains on lead SMARCA2 cancer asset
The biotech is directing energy toward another SMARCA2 degrader, its sole remaining clinical-stage asset.
Darren Incorvaia
Aug 14, 2025 10:44am
Galapagos builds island of cell therapies amid pipeline pruning
Jul 24, 2025 10:59am
Relmada dumps depression asset after slew of phase 3 failures
Jul 11, 2025 12:12pm
Karyopharm lays off 20% of staffers amid hunt for alternatives
Jul 11, 2025 11:02am
Cellectar seeks strategic alternatives, sinking stock
Apr 30, 2025 10:41am
Elevation faces activist investor demands to wind down
Apr 17, 2025 10:00am
